Modulation of Innate Immunity by G-CSF and Inflammatory Response by LBPK95A Improves the Outcome of Sepsis in a Rat Model
Open Access
- 7 November 2018
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-12
Abstract
Introduction. Sepsis is the primary cause of death from infection. We wanted to improve the outcome of sepsis by stimulating innate immunity in combination with modulating the severity of inflammatory responses in rats.Method. Sepsis was induced by the injection of feces suspension (control). A 5-day course of G-CSF treatment was given before the septic insult (G-CSF). The inflammatory response was decreased using various doses of the LPS-blocking peptide LBPK95A (Combi group,Combi group, andCombi group). Survival rates were observed. Bacterial clearance, neutrophil infiltration, tissue damage, and the induction of hepatic and systemic inflammatory responses were determined 2 h and 12 h after the septic insult.Results. High-dose LBPK95A (100% Combi) reduced the survival rate to 10%, whereas low-dose LBPK95A (10% and 1% Combi) increased the survival rates to 50% and 80%, respectively. The survival rates inversely correlated with multiorgan damage as indicated by the serum levels of ALT and urea. G-CSF treatment increased the white blood cell counts, hepatic neutrophil infiltration, and bacterial clearance in the liver, lung, and blood. The blockade of the LPS-LBP interaction decreased neutrophil infiltration, led to increased white blood cell count, and decreased hepatic neutrophil infiltration, irrespective of dose. However, bacterial clearance improved in the 1% and 10% Combi groups but worsened in the 100% Combi group. G-CSF increased TNF-αand IL-6 levels. Irrespective of dose, the blockade of the LPS-LBP interaction was associated with low systemic cytokine levels and delayed increases in hepatic TNF-αand IL-6 mRNA expression. The delayed increase in cytokines was associated with the phosphorylation of STAT3 and AKT.Conclusion. Our results revealed that increasing innate immunity by G-CSF pretreatment and decreasing inflammatory responses using LBPK95A improved the survival rates in a rat sepsis model and could be a novel strategy to treat sepsis.
Keywords
Funding Information
- National Natural Science Foundation of China (81401617)
- Bundesministerium für Forschung, Technologie und Raumfahrt (81401617)
This publication has 41 references indexed in Scilit:
- Granulocyte Colony Stimulating Factor Induces Lipopolysaccharide (LPS) Sensitization via Upregulation of LPS Binding Protein in RatPLOS ONE, 2013
- Endotoxemia and mortality prediction in ICU and other settings: underlying risk and co-detection of gram negative bacteremia are confoundersCritical Care, 2012
- Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition moleculeBiochemical Society Transactions, 2011
- Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysisCritical Care, 2011
- G-CSF Administration in a Small-for-Size Liver ModelJournal of Investigative Surgery, 2009
- Effects of Granulocyte-Colony Stimulating Factor on the Polymorphonuclear Leukocyte Activity and the Course of Sepsis in Rats with Experimental PeritonitisSurgery Today, 2007
- Modulatory effects of sCD14 and LBP on LPS-host cell interactionsInnate Immunity, 2005
- How to leverage an endogenous immune defense mechanism: The example of granulocyte colony-stimulating factorCritical Care Medicine, 2003
- Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in ratsCritical Care Medicine, 1996
- Endogenous haemopoietic growth factors in neutropenia and infectionBritish Journal of Haematology, 1994